The invention pertains to the use of a supplement for making metals (nutritionally) available to animals, said supplement comprising at least one compound selected from the group consisting of glutamic acid N,N-diacetic acid (GLDA), a metal complex of GLDA, a sodium salt of GLDA, a potassium salt of GLDA, methylglycine-N,N-diacetic acid (MGDA), a metal complex of MGDA, a sodium salt of MGDA, a potassium salt of MGDA, ethylenediamine N,N′-disuccinic acid (EDDS), a metal complex of EDDS, a sodium salt of EDDS, a potassium salt of EDDS, iminodisuccinic acid (IDS), a metal complex of IDS, a sodium salt of IDS, and a potassium salt of IDS.

The present invention relates to an edible product, which comprises a fibrous plant product and a plant extract applied thereto. Further, the invention relates to a corresponding method for producing said edible product and its use in at least one of food, food supplement, medicinal, cosmetic, well-being, nutraceutical or phytotherapeutical applications. The plants used may be all plants comprising one or more substances of interest for an edible product.

Provided is an inactive compound that is activated by reaction with ozone into an active compound having a carbonyl oxygen. Also provided is a method of activating the above inactive compounds. Further provided is a method of treating a disease or condition in a subject using the above compound at a site that is not exposed to atmospheric ozone. Additionally provided is a method of determining internal ozonolysis in a subject using the above compound. Also provided is a molecule less than 1000 mw, having a double bond that is reactive with ozone, and forms a nontoxic compound after reacting with ozone. Further provided is a method of degrading ozone.

The invention relates to formula comprising a combination of urea and non-digestible oligosaccharides, for improved stimulation of the growth of Bifidobacteria in the intestinal microbiota of infants or young children.

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides TβRII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.

In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same.

The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof

The present invention provides: a feed for reducing lipid peroxide or improving meat quality in a tissue in an edible portion of a domestic animal, the feed comprising a spore-bearing lactic acid bacterium and/or a spore-bearing thermophilic bacterium not corresponding to the spore-bearing lactic acid bacterium; and a food for reducing lipid peroxide in a human body, the food comprising a spore-bearing lactic acid bacterium and/or a spore-bearing thermophilic bacterium not corresponding to the spore-bearing lactic acid bacterium.

Embodiments of a composition and/or combination comprising an anionic dietary supplement and 25-hydroxy vitamin D are disclosed. The anionic dietary supplement may be a negative dietary cation anion difference (DCAD) supplement and/or may comprise magnesium chloride, magnesium sulfate, ammonium chloride, ammonium sulfate, and calcium sulfate, and/or complexes thereof. Also disclosed are embodiments of a method for administrating the combination and/or composition to an animal, such as a ruminant. In certain embodiments, the animal is a dairy cow, and the method may be a method for increasing milk yield, and/or improving the health of the animal.